[ad_1]
Synopsis
The deal ought to drive the next leg of growth for Biocon. However, with no experience of commercialising biosimilars in developed markets, can it succeed where a large company like Viatris could not make a big impact? Besides, increasing debt is also fuelling concern.
In 2017, when the US Food and Drug Administration (USFDA) approved the first biosimilar of breast-cancer drug trastuzumab, it was a big validation for Biocon’s development capabilities. Founder Kiran Mazumdar-Shaw described it as a “crowning moment” for the company, a result of its relentless work in the biosimilars space and navigation through several hurdles over the years. Shaw had placed bets on biosimilars in the early 2000s, much before
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link
